Brain Imaging Study on Biomarkers for Fibromyalgia
A legfontosabb adatok
- Ki végzi
- Nova Scotia Health Authority
- Hol
- Kanada1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 35 fő, tervezett
- Kezdés
- 2021. febr. 1.
- Várható befejezés
- 2035. jan.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
- A vizsgált kezelések
- Placebos
- A regiszteradat frissítve
- 2024. augusztus 22.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with long-lasting pain (the record names fibromyalgia and chronic low back pain), and healthy volunteers without pain. Everyone has brain scans (MRI).
- Életkor
- 18 to 75 years
- Nem
- All sexes
- A betegség stádiuma
- Pain group: low back pain for more than 6 months, with average pain of at least 4/10 on the Brief Pain Inventory Scale in the two weeks before joining. Healthy group: no acute or chronic pain.
A részvétel fő kizáró okai
- Not right-handed
- Not comfortable reading and writing questionnaires and tasks in English
- Heart, breathing or nervous system disease that could interfere or raise the risk, such as asthma or fear of closed spaces
- Anything that rules out an MRI scan, such as a pacemaker, metal implants or pregnancy
- For healthy volunteers: any acute or chronic pain
A regiszter feltételei, szó szerint
Mind a 10 feltétel megnézéseKevesebb
Ki vehet részt
- Chronic pain participant inclusion criteria:; 18-75 years of age; Right-handed; Meet the classification criteria of chronic low back pain (having low back pain for more than 6 months); At least 4/10 clinical pain on the Brief Pain Inventory Scale on average during the two weeks prior to enrollment; Comfortable completing (reading and writing) questionnaires and tasks with English language instructions; Healthy participant inclusion criteria:
- 18 - 75 years of age
- Right-handed
- Comfortable completing (reading and writing) questionnaires and tasks with English language instructions
Ki nem vehet részt
- History of cardiac, respiratory, or nervous system disease that may interfere with participation in the study or cause heightened potential for adverse outcome. For example: asthma or claustrophobia
- Presence of any contraindications to MRI scanning. For example:; cardiac pacemaker, metal implants, fear of closed spaces, pregnancy; Healthy participant exclusion criteria:
- History of cardiac, respiratory, or nervous system disease that, in the investigator's judgment and by asking the participant about their comfort level and ability, precludes participation in the study because of a heightened potential for adverse outcome. For example: asthma or claustrophobia
- Presence of any contraindications to MRI scanning. For example:; cardiac pacemaker, metal implants, fear of closed spaces, pregnancy
- Chronic pain participant exclusion criteria:
- Acute or chronic pain
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Drugs used for managing Fibromyalgia pain have not proven to be effective and pain continues to cost Canadians $60 billion a year without truly helping those who suffer. The study proposes to investigate the factors related to a person that can enhance or reduce the effectiveness of pain treatments in people suffering with Fibromyalgia pain. Treatment response to painkillers in a person may be related to their brain, social, and psychological makeup. The investigators aim to study these factors to identify and develop feasible and robust indicators based on a person's biological makeup (also called biomarkers). These biomarkers will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people. These measures will offer new opportunities for improving treatment such as by tailoring treatment to meet the specific needs of each patient based on his/her biological and psychological makeup. Towards the specific aim, data will first be collected in several experimental domains for studying treatment expectations (cognitive, psychosocial, brain-related). These 'experimental' data will be compared between Fibromyalgia (FM) and healthy participants to yield new understanding of the factors that govern treatment response. At the end of experimental data collection, the investigators will collect data in the 'clinical' domain. Hence, at the end of the experimental sessions, a subset of FM participants will receive a mock drug (placebo disguised as an approved pain treatment) and another subset will provide pain ratings only and hence serve as a waiting list control for the placebo trial. Data will be studied in steps to understand factors that mediate treatment outcomes and finally the investigators will use advanced computational tools used for big data analysis and aim to identify factors that can be used as biomarkers and precision medicine tools.
A vizsgálat 3 csoportja
- Experimental: placebosA vizsgált kezelés
Fibromyalgia participants will enter in an optional placebo trial. This phase of the study will test the clinical usefulness of the biomarkers. We will measure how expectation of starting a new treatment reduces 'clinical back pain' in each participant. Positive treatment expectations will be induced by giving them capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
Kezelés: Placebos
- WaitlistNincs vizsgálati kezelés, összehasonlításként
Fibromyalgia participants will not be given any placebo and will be requested to report their pain on paper forms organized as a calendar or on REDCap.
- Healthy ControlsNincs vizsgálati kezelés, összehasonlításként
Healthy control participants will complete the main part of the study, but will not be asked to take a placebo or be placed on a waitlist.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT03910010: ki vehet részt
- A regiszteradat frissítve
- 2024. augusztus 22.